• Corpus ID: 44755775

Iodine-123-4-amino-3-iodobenzylguanidine, a new sympathoadrenal imaging agent: comparison with iodine-123 metaiodobenzylguanidine.

@article{Shulkin1986Iodine1234amino3iodobenzylguanidin,
  title={Iodine-123-4-amino-3-iodobenzylguanidine, a new sympathoadrenal imaging agent: comparison with iodine-123 metaiodobenzylguanidine.},
  author={Barry L. Shulkin and Brahm Shapiro and Michael C. Tobes and S W Shen and Donald M. Wieland and Laura J. Meyers and H T Lee and Neil A. Petry and James C. Sisson and William H. Beierwaltes},
  journal={Journal of nuclear medicine : official publication, Society of Nuclear Medicine},
  year={1986},
  volume={27 7},
  pages={
          1138-42
        }
}
Iodine-123-4-amino-3-iodobenzylguanidine ([123I]AIBG), an analog of 123I metaiodobenzylguanidine ([123I]MIBG), has an advantage in having a more rapid and simple synthesis. This, combined with animal data that suggested a greater affinity of the new radiopharmaceutical for the autonomic innervation of the myocardium led us to study the biodistribution of [123I]AIBG in three men with metastatic pheochromocytoma. In all instances, [123I]AIBG revealed the same metastatic deposits shown by [123I… 
View on PubMed
jnm.snmjournals.org
23 Citations
Background Citations
3
Methods Citations
1

Tables from this paper

23 Citations

Contributions of nuclear endocrinology to the diagnosis of adrenal tumors.

  • B. ShapiroL. FigM. GrossF. Khafagi
  • Medicine, Biology
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer
  • 1990
The scintigraphic evaluation of the adrenal cortex with [131I] 6β-iodomethylnorcholesterol (NP-59) and the sympathomedullary system with [131I]- or [123I]-metaiodobenzylguanidine (MIBG) provides a…

Ring-and side-chain-substituted MIBG analogues

A number of ring- and side-chain substituted analogues of MIBG are synthesized and their lipophilicity, stability in vitro, uptake in SK-N-SH human neuroblastoma cells and tissue distribution in normal mice are evaluated.

Nuclear medicine imaging of neuroendocrine tumours.

This Review summarizes the potential of several nuclear medicine techniques in the diagnosis of neuroendocrine tumours and stresses the renewed role of nuclear -medicine in the management of this disease.

Radioiodinated metaiodobenzylguanidine: a review of its biodistribution and pharmacokinetics, drug interactions, cytotoxicity and dosimetry

Iodine-131 metaiodobenzylguanidine therapy is in general well tolerated, but its effectiveness needs improvement and whole-body dosimetry as part of treatment planning needs to be improved.

Lung-uptake and -washout of MIBG in sarcoidosis.

Herz-affinität von radioaktiven ruthenocen-derivaten des chinuclidin-3-ol

Durch Kondensation von Ferrocenaldehyd mit Chinuclidin-3-on wurde 2-Ferrocenyliden-chinuclidin-3-on hergestellt und anschliesend die Ketogruppe reduziert. Durch Zentralatom-Austausch erhielt man die…

Positron emission tomography (PET) and other nuclear medicine modalities in staging gastrointestinal cancer.

This work aims to summarize the current status of the most important approaches and their main indications in staging GI cancers.

Roles of cardiac sympathetic neuroimaging in autonomic medicine

Cardiac sympathetic neuroimaging by 123I-MIBG scanning merits consideration as an autonomic test, especially in patients with nOH.

Imaging hNET Reporter Gene Expression with 124I-MIBG

The construction of an internal ribosomal entry site (IRES)-linked hNET-green fluorescent protein (GFP) hybrid reporter gene for both nuclear and optical imaging demonstrates the potential for a wider application of hNET reporter imaging and the future translation to patient studies using radiopharmaceuticals.

Myocardial scintigraphy — 25 years after start

  • G. Hör
  • Medicine
    European Journal of Nuclear Medicine
  • 2004
The present state of MS in coronary heart disease is discussed for single and multivessel disease, previous infarction, and risk stratification, reflecting the importance of the procedure in exercise-induced ischemia as well as in ischemic dilation for prognostication of the natural and therapeutic course.

References

SHOWING 1-9 OF 9 REFERENCES

Portrayal of pheochromocytoma and normal human adrenal medulla by m-[123I]iodobenzylguanidine: concise communication.

Diagnostic doses of MIBG labeled with I-131 and I-123, with nearly equivalent radiation dosimetry, were compared as imaging agents in eight patients with known or suspected pheochromocytoma, and Iodine-123 has many potential advantages over I- 131 as a radiolabel for M IBG, including shorter half-life, freedom from beta emissions, and increased gamma-camera efficiency.

The normal and abnormal distribution of the adrenomedullary imaging agent m-[I-131]iodobenzylguanidine (I-131 MIBG) in man: evaluation by scintigraphy.

The scintigraphic distribution of m-[131I]iodobenzylguanidine (I-131 MIBG), an adrenal medullary imaging agent, was studied to determine the patterns of uptake of this agent in man and includes clear portrayal of the salivary glands, liver, spleen, and urinary bladder.

Effect of uptake-one inhibitors on the uptake of norepinephrine and metaiodobenzylguanidine.

The mechanisms underlying the uptake of the radiopharmaceutical metaiodobenzylguanidine and the catecholamine norepinephrine were studied using cultured bovine adrenomedullary cells as an in vitro model system and iodine-131 MIBG scintigraphy of the adrenal appears to reflect uptake by way of the Uptake-one system.

Scintigraphic localization of pheochromocytoma.

A new radiopharmaceutical agent, [ 131I]meta-iodobenzylguanidine ([131I]MIBG), is used to produce scintigraphic images of pheochromocytomas in eight patients, offering hope of safe and reliable localization of p heochromocytes in their many guises.

Iodine-131 metaiodobenzylguanidine for the locating of suspected pheochromocytoma: experience in 400 cases.

Iodine-131 MIBG scintigraphy was found to be a safe, noninvasive, and efficacious technique for the location of pheochromocytomas, especially for those arising from nonadrenal sites, recurring postoperatively, and exhibiting malignant metastatic disease.

Radi opharmaceutical treatment of malignant pheochro mocytoma.J

  • NuciMed 24:197—206,
  • 1984

Devel opment of a kit-form analog of metaiodobenzylgua nidine

  • J Nuci Med
  • 1986

Myocar dial imaging in man with 1-123 metaiodobenzylgua nidine

  • JNuclMed
  • 1981

Synthesis of 1-131 and I-l23-metaiodobenzylguani dine (MIBG) in the diagnosis and treatment of pheo chromocytoma

  • J Nuci Med 24:
  • 1983